Skip to main content
. Author manuscript; available in PMC: 2020 Sep 3.
Published in final edited form as: J Neurosurg. 2018 Dec 1;129(6):1397–1406. doi: 10.3171/2017.7.JNS171286

FIG. 1.

FIG. 1.

Tumor (upper) and edema (lower) volume trajectories after SRS for no ipilimumab (dashed line), concurrent ipilimumab (dotted-dashed line), and nonconcurrent ipilimumab (solid line) at fixed time points. **Statistically significant difference.